Details for New Drug Application (NDA): 078775
✉ Email this page to a colleague
NDA 078775 describes STAVUDINE, which is a drug marketed by Aurobindo Pharma, Hetero Labs Ltd Iii, Pharmobedient, and Cipla Ltd, and is included in six NDAs. Additional details are available on the STAVUDINE profile page.
The generic ingredient in STAVUDINE is stavudine. There are fourteen drug master file entries for this compound. Additional details are available on the stavudine profile page.
The generic ingredient in STAVUDINE is stavudine. There are fourteen drug master file entries for this compound. Additional details are available on the stavudine profile page.
Summary for 078775
| Tradename: | STAVUDINE |
| Applicant: | Pharmobedient |
| Ingredient: | stavudine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 078775
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 30MG | ||||
| Approval Date: | Jan 5, 2009 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 40MG | ||||
| Approval Date: | Jan 5, 2009 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
